Genmab AS (GMAB) — Capital Reinvestment Ratio
Latest as of December 2025:
0.04x
Genmab AS (GMAB) has a Capital Reinvestment Ratio of 0.04x as of December 2025, meaning it reinvests 0% of its operating cash flow ($300.34 Million) in capital expenditures ($12.99 Million). See GMAB FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.04x
Capex / Operating Cash Flow
Operating Cash Flow
$300.34 Million
USD
Capital Expenditures
$12.99 Million
USD
Data as of
Dec 2025
Most recent filing
Genmab AS Capital Reinvestment Ratio (2007–2025)
This chart tracks Genmab AS's Capital Reinvestment Ratio across 15 annual periods.
Annual Capital Reinvestment Ratio for Genmab AS (2007–2025)
Year-by-year Capital Reinvestment Ratio for Genmab AS from 2007 to 2025. For live market cap and broader valuation context, see Genmab AS (GMAB) total market value.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.03x | $1.19 Billion | $37.03 Million | ▲ +29.6% |
| 2024 | 0.02x | $7.77 Billion | $187.00 Million | ▼ -52.8% |
| 2023 | 0.05x | $7.38 Billion | $376.00 Million | ▼ -37.1% |
| 2022 | 0.08x | $3.91 Billion | $317.00 Million | ▼ -28.4% |
| 2021 | 0.11x | $2.23 Billion | $252.00 Million | ▲ +137.0% |
| 2020 | 0.05x | $6.43 Billion | $307.00 Million | ▼ -43.0% |
| 2019 | 0.08x | $1.33 Billion | $111.00 Million | ▼ -82.2% |
| 2018 | 0.47x | $1.01 Billion | $477.37 Million | ▲ +744.5% |
| 2017 | 0.06x | $1.59 Billion | $88.51 Million | ▼ -44.9% |
| 2016 | 0.10x | $327.72 Million | $33.11 Million | ▼ -76.8% |
| 2015 | 0.43x | $311.45 Million | $135.39 Million | ▼ -23.6% |
| 2014 | 0.57x | $132.67 Million | $75.44 Million | ▲ +348.2% |
| 2012 | 0.13x | $70.92 Million | $9.00 Million | ▲ +236.5% |
| 2010 | 0.04x | $268.17 Million | $10.11 Million | ▲ +48.5% |
| 2007 | 0.03x | $505.90 Million | $12.84 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow